Compare Davita Inc (DVA) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Thomson Reuters Corp — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Thomson Reuters Corp trades at $104.52 (market cap $45.08B). The key difference: Thomson Reuters Corp is far larger — about 3.8× Davita Inc's market cap, and Thomson Reuters Corp pays a 2.51% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | TRI | |
|---|---|---|
Market Cap | $11.72B | $45.08B |
Sector | Health | Industrials |
52-Week High | $240.96 | $178.77 |
52-Week Low | $103.87 | $76.55 |
Enterprise Value | $24.44B | $47.69B |
Dividend Yield | — | 2.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Thomson Reuters (TRI) trades at $101.83, up 1.68% today, near the consensus price target of $102.33. The stock shows strong technical momentum with bullish moving averages and support at $99. Fundamentally, TRI delivered Q2 2026 earnings beat ($0.99 vs. $0.96 expected) with 8% organic revenue growth, while maintaining robust profitability margins (21.22% net income margin). Recent news highlights AI-driven product momentum and raised full-year revenue guidance.
Outlook remains positive with analyst consensus favoring Buy (51.85%) and 29.8% upside potential to high target of $124. Key risks include execution on AI transition and competitive pressures in legal/tax software markets. The company's recurring revenue model (82% of total) and dividend payments provide stability amid growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
